Viridans Streptococci: Diversity, Oral Role, and Antibiotic Resistance

Viridans group streptococci are among the most abundant bacteria in the human mouth, colonizing oral surfaces within hours of birth and persisting throughout life. Despite their ubiquity, they are remarkably difficult to classify, surprisingly versatile as both protectors and pathogens, and increasingly resistant to common antibiotics. The term “viridans” itself is somewhat misleading, a loose label for a collection of streptococcal species that share a few traits but differ in meaningful ways, from the sugars they ferment to the diseases they cause.

What Counts as a Viridans Streptococcus

The viridans group streptococci (often abbreviated VGS) are not a single species or even a tightly defined group. They are a grab-bag of species that share two negative characteristics: they are not Group A or Group B streptococci, and they are not Streptococcus pneumoniae. Most produce a greenish (alpha-hemolytic) discoloration on blood agar plates, which is where the name comes from, but some are non-hemolytic, and a few can be beta-hemolytic under certain conditions. The group is typically sorted into five or six subgroups based on genetic and biochemical similarities: Mitis, Salivarius, Mutans, Anginosus, and Bovis, with some classification schemes adding a Sanguinis group.

Each subgroup has its own personality. The Mitis group, which includes species like Streptococcus mitis, S. oralis, and S. gordonii, dominates the cheek and tongue surfaces. The Mutans group, headlined by S. mutans, is the chief villain in tooth decay. The Anginosus group tends to cause abscesses in deep tissues. The Salivarius group lives mostly on the tongue and in saliva. The Bovis group hangs out lower in the gut and has a well-documented link to colorectal disease. These groupings matter clinically because they predict, at least roughly, what kind of trouble a given isolate might cause.

Why Identifying Them Is Genuinely Hard

Even with modern technology, pinning a species name on a viridans streptococcal isolate remains one of the more frustrating tasks in a clinical microbiology lab. Conventional biochemical tests and older automated systems miss a lot. One study comparing a commercial biochemical system (API STREP) with a mass spectrometry platform (MALDI-TOF MS) against 16S rRNA gene sequencing as the reference standard found that the biochemical system correctly identified only about 61% of isolates, while MALDI-TOF managed about 65%. For the Mitis group specifically, the biochemical system’s sensitivity was just 48%, whereas MALDI-TOF reached 80%.¹ That leaves a large gap, and the authors concluded that no single method is sufficient on its own.

MALDI-TOF mass spectrometry has improved matters, but performance depends heavily on which platform and which reference database you use. A comparison of two major commercial systems found that one (VITEK MS) accurately identified about 95% of VGS isolates, while the other (Bruker Biotyper) managed about 90%.² A persistent sticking point is the inability of some systems to tell S. mitis apart from S. oralis, two closely related species within the Mitis group.³ When labs need a definitive species-level answer, gene sequencing of targets like 16S rRNA or rpoB is often the only reliable route. An in-house MALDI-TOF method using an extraction step and a carefully curated database achieved 95% species-level accuracy, suggesting that better databases, not necessarily better hardware, are the bottleneck.⁴

The practical consequence of this identification fog is that clinical decisions sometimes have to be made before a precise species name is available, or with an identification that may be wrong. This is especially problematic when choosing antibiotics, because resistance patterns differ between species and between subgroups.

First Inhabitants of the Mouth

Oral streptococci are among the first bacteria to move into the mouth after birth, and they play a foundational role in assembling the rest of the oral microbial community.⁵ They do this by colonizing the soft tissue surfaces of the mouth, tongue, and cheeks and by producing adhesins that let them stick to mucosal cells. Once teeth erupt in infancy, new niches open up, and species like S. mutans and S. sanguinis colonize the hard enamel surfaces.

What makes this early colonization important is that it shapes which other bacteria can and cannot establish themselves later. The biofilm that builds on tooth surfaces is a layered structure, with viridans streptococci forming much of the initial scaffold. Some of these early colonizers actively defend their territory. Streptococcus gordonii, for instance, produces hydrogen peroxide under certain environmental conditions, and this hydrogen peroxide has a direct antagonistic effect on many bacterial species in the mouth, including a number of pathogens.⁶ This kind of chemical warfare helps keep potential invaders in check and is one reason a healthy viridans streptococcal population is considered protective.

The Role of S. mutans in Tooth Decay

Not all viridans streptococci are helpful neighbors. Streptococcus mutans is the species most strongly associated with dental caries, and the way it builds biofilm is central to how cavities form. S. mutans produces enzymes called glucosyltransferases that synthesize sticky sugar polymers (glucans) directly on the tooth surface. These glucans serve as both a glue and a scaffold, providing binding sites for other microorganisms and creating an insoluble matrix that shields the bacterial community from saliva’s buffering and antimicrobial effects.⁷ Under this matrix, the bacteria ferment dietary sugars and produce acid, which gradually dissolves enamel.

The same glucan-producing machinery that makes S. mutans dangerous for teeth also appears in the pathogenesis of more serious infections. Dextran, a type of glucan, enhances the ability of oral streptococci to stick to damaged heart valves, as discussed in the next section. Understanding this shared molecular toolkit helps explain how mouth bacteria can cause disease in distant organs.

When Mouth Bacteria Reach the Bloodstream

Brushing your teeth, flossing, and especially dental procedures can push oral streptococci into the bloodstream. For most people, the immune system clears these transient episodes quickly and without symptoms. But in certain settings, viridans streptococci in the blood can cause serious harm.

The most classic scenario is infective endocarditis, an infection of the heart’s inner lining or valves. VGS have long been among the leading causes. The mechanism involves bacterial adhesion to damaged or abnormal valve tissue. In lab models simulating the kind of fibrin-platelet deposits that form on damaged valves, Streptococcus sanguis adhered much more readily to a fibrin-platelet matrix than to fibrin alone, and dextran production by the bacteria significantly enhanced this adhesion.⁸ Some strains of S. sanguis also interact directly with platelets, adhering to them and even triggering them to clump, which may help vegetations grow on the valve surface.⁹

The Anginosus group presents a different threat. These species are notable for their tendency to cause abscesses in deep tissues, including the brain, liver, and lungs. As opportunistic pathogens, they can produce pyogenic infections in patients of all ages with no particular gender bias, though the three species within the group (S. anginosus, S. constellatus, and S. intermedius) differ in which body sites they most often infect.¹⁰

Perhaps the most dangerous context for viridans streptococcal bloodstream infection is in cancer patients whose immune defenses have been wiped out by chemotherapy. In a study of neutropenic patients with VGS bacteremia, about 11% developed serious complications such as septic shock, acute respiratory distress syndrome, or both. The mortality rate among patients with these complications was stark: 80%, compared with roughly 18% in those without complications. Severe oral mucositis, high-dose cyclophosphamide chemotherapy, and allogeneic bone marrow transplantation were the factors most strongly linked to these devastating outcomes.¹¹

How They Dodge the Immune System

A bacterium that lives in the human mouth every day of your life has had a long evolutionary training program in evading immune surveillance. Streptococcus mitis, one of the most common oral species, produces an immunoglobulin A protease that cleaves a key antibody found in saliva, effectively blinding one of the mouth’s main immune defenses.¹² It also modulates host immune responses in subtler ways, using surface adhesins and toxins that help it maintain its niche without triggering a full inflammatory response. This balancing act is what lets it persist as a commensal, but the same immune-evasion tools become dangerous when the bacterium ends up in the wrong place, such as on a heart valve.

S. mutans has its own complement-evasion strategy. The bacterium uses a signaling system (a two-component regulatory system) that controls peptidases capable of interfering with complement, a branch of the immune system that normally tags bacteria for destruction.¹³ These evasion tactics help explain why viridans streptococci can persist in the bloodstream long enough to seed infections on heart valves or in deep tissues, rather than being cleared immediately.

The Rising Problem of Antibiotic Resistance

For decades, viridans streptococci were considered reliably sensitive to penicillin, making them relatively easy to treat when they caused infections. That assumption has eroded. A large international surveillance study (SENTRY program, covering 1997 through 2000) found that only about 69% of viridans group streptococci were susceptible to penicillin. Erythromycin susceptibility was even lower, at around 65%. The only agents with universal activity were vancomycin, teicoplanin, and linezolid, all at 100%.¹⁴ These numbers are from over two decades ago, and resistance has generally trended upward since then.

The mechanism behind penicillin resistance in VGS involves alterations in penicillin-binding proteins, the enzymes that penicillin normally targets. Researchers have identified diverse sequence variants (alleles) of the PBP2x gene in species like S. mitis, S. oralis, and S. infantis, with dozens of distinct mutation sites within the critical enzymatic domain. These mutations reduce the drug’s ability to bind its target, allowing the bacterium to continue building its cell wall despite the presence of the antibiotic.¹⁵

Macrolide resistance follows a different pattern. In viridans streptococci, two main resistance mechanisms operate. One involves a protein (encoded by the erm family of genes) that chemically modifies the ribosome so that macrolide antibiotics can no longer bind. This type confers cross-resistance to macrolides, lincosamides, and streptogramin B antibiotics all at once. The other involves an efflux pump (encoded by mef genes) that actively pumps the drug out of the bacterial cell, conferring resistance mainly to 14- and 15-membered macrolides. One study of viridans streptococci found a macrolide resistance rate of about 28%, with the ribosome-modifying phenotype dominant in the Anginosus group and the efflux phenotype predominant in S. mitis and S. oralis.¹⁶

Quinolone resistance, though less discussed, is clinically relevant, especially in cancer patients receiving quinolone prophylaxis. Mutations in the gyrA and parC genes, which encode the enzymes that quinolones target, have been detected in quinolone-resistant isolates from the mouths of neutropenic transplant patients on fluoroquinolone prophylaxis.¹⁷ The selective pressure from prophylactic antibiotics appears to drive this emergence.

The Reservoir Problem and Gene Sharing With S. pneumoniae

Perhaps the most far-reaching consequence of antibiotic resistance in viridans streptococci is not about treating VGS infections themselves. It is about what happens when these oral bacteria share their resistance genes with Streptococcus pneumoniae, a major cause of pneumonia, meningitis, and ear infections worldwide.

Because VGS species like S. mitis and S. oralis are closely related to S. pneumoniae, their DNA is compatible enough for genetic recombination. In transformation experiments, the majority of penicillin-resistant S. mitis and S. sanguis strains were able to transfer penicillin resistance genes directly into S. pneumoniae.¹⁸ This is not just a laboratory curiosity. Genomic analysis of fluoroquinolone-resistant S. pneumoniae clinical isolates revealed mosaic gene structures in their topoisomerase genes (the targets of fluoroquinolones), with segments that matched S. mitis and S. oralis sequences, including a marker gene found in viridans streptococci but absent from typical S. pneumoniae.¹⁹

The same dynamic applies to macrolide resistance. The mef and related efflux-pump genes were successfully transferred from viridans streptococci to S. pneumoniae in the lab, confirming that VGS and related commensals serve as important reservoirs of resistance genes for a far more dangerous pathogen.²⁰ This means that antibiotic use that selects for resistance in your harmless oral streptococci can, over time, arm a respiratory pathogen against the same drugs. It is one of the clearest examples of how commensal bacteria function as a genetic library that pathogens can borrow from.

Antibiotic Prophylaxis Before Dental Work

Given that dental procedures can push viridans streptococci into the bloodstream, a long-standing clinical question has been whether giving antibiotics before dental work prevents infective endocarditis. Guidelines on this have shifted considerably over the years, generally narrowing the group of patients considered to benefit. The list of medical conditions requiring prophylaxis has been shortened in response to concerns about antibiotic resistance and unnecessary prescribing.²¹

Current guidelines from the American Heart Association and the European Society of Cardiology recommend prophylaxis only for patients at the highest risk of endocarditis, including those with prosthetic heart valves, previous endocarditis, certain congenital heart defects, or cardiac transplant recipients with valve disease. For these high-risk patients, the evidence supports the practice. A systematic review and meta-analysis found that antibiotic prophylaxis was associated with a roughly 59% lower risk of endocarditis after invasive dental procedures in high-risk individuals.²² A large case-crossover study further showed that the risk was greatest after dental extractions and oral surgery, and that prophylaxis significantly reduced the association between these procedures and subsequent endocarditis.²³

For people at low or unknown risk, however, no benefit of prophylaxis has been demonstrated. There is also insufficient data to support it for moderate-risk patients. This means the vast majority of people heading to the dentist do not need a pre-procedure antibiotic, and giving one would contribute to resistance pressure without a demonstrated payoff.

Oral Probiotics and Streptococcus salivarius

If some viridans streptococci protect the mouth by producing hydrogen peroxide and outcompeting pathogens, a natural question is whether you can deliberately introduce beneficial strains. This idea has progressed furthest with Streptococcus salivarius K12, a strain from the Salivarius group that has been developed as an oral probiotic. Safety assessments have found it well-tolerated, and it has excellent potential for use as a probiotic targeting the oral cavity.²⁴

Research has gone beyond just K12. Screening of streptococcal strains isolated from the throats of healthy donors identified additional candidates, including S. salivarius RS1 and ST3, that efficiently bound to human pharyngeal cells and antagonized both the adhesion and growth of Streptococcus pyogenes, the bacterium responsible for strep throat.²⁵ The concept is to use the mouth’s own native residents, selected for their competitive traits, to crowd out pathogens. Lozenges and chewing gums containing S. salivarius K12 are already commercially available in several countries, marketed primarily for throat and ear health in children, though the clinical evidence base is still growing.

The probiotic approach highlights a broader shift in how researchers think about viridans streptococci. Rather than viewing the oral microbiome as a passive backdrop to disease, the emerging picture is one of active ecological competition, where the balance between protective and harmful species determines outcomes as much as any single pathogen does. Maintaining that balance, through good oral hygiene, avoiding unnecessary antibiotics, and potentially supplementing with beneficial strains, may prove as important as fighting infections after they start.